drugset
Drugs / EMD 1201081
last change Jan 2015 re-read 2 minutes ago

EMD 1201081

also known as IMO-2055 · HYB-2055 · IMOxine

Oligonucleotide (other) targets TLR9 via activation

Developed for
head and neck squamous cell carcinoma · colorectal cancer · non-small cell lung carcinoma · clear cell renal carcinoma
Investigated by
EMD Serono · Merck KGaA, Darmstadt, Germany

Trials 4 · a red edge is where a trial was stopped

today NCT01360827 · Ph 1 NCT01040832 · Ph 2 NCT00719199 · Ph 1 NCT00633529 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01360827 Aug 2010 → Apr 2011 head and neck squamous cell carcinoma Merck KGaA, Darmstadt, Germany Terminated No outcome recorded
Phase 1 NCT00719199 Jan 2009 → Apr 2011 colorectal cancer EMD Serono Terminated No outcome recorded
Phase 1 NCT00633529 Nov 2007 → Oct 2010 non-small cell lung carcinoma EMD Serono Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01040832 Dec 2009 → Jan 2012 head and neck squamous cell carcinoma EMD Serono Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00729053 Comparator Jun 2004 → Apr 2008 clear cell renal carcinoma Idera Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as EMD 1201081 “The immune modulatory oligonucleotide IMO-2055 (EMD 1201081) is a phosphorothioate oligodeoxynucleotide agonist of Toll-like receptor 9.” PMID 25627002 ↗ Jan 2015
2

NCT01360827 ↗

NCT01040832 ↗
Known as HYB-2055 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297993 ↗
Known as IMO-2055 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00729053 ↗
2

NCT00719199 ↗

NCT00633529 ↗
Known as IMOxine “IMOxine® (IMO-2055 for Injection)” NCT00729053 ↗
Action Activate “agonist of Toll-like Receptor 9 (TLR9)” NCT00719199 ↗
Modality Oligonucleotide (other) “IMO-2055 (EMD 1201081) is a phosphorothioate oligodeoxynucleotide agonist” PMID 25627002 ↗ Jan 2015
Route Subcutaneous “weekly subcutaneous IMO-2055” NCT00633529 ↗
Target TLR9 “agonist of Toll-like Receptor 9 (TLR9)” NCT00719199 ↗